Amyloid β induces interneuron-specific changes in the hippocampus of APPNL-F mice

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by cognitive decline and amyloid-beta (Aβ) depositions generated by the proteolysis of amyloid precursor protein (APP) in the brain. In APPNL-F mice, APP gene was humanized and contains two familial AD mutations, and APP–unlike other mouse models of AD–is driven by the endogenous mouse APP promoter. Similar to people without apparent cognitive dysfunction but with heavy Aβ plaque load, we found no significant decline in the working memory of adult APPNL-F mice, but these mice showed decline in the expression of normal anxiety. Using immunohistochemistry and 3D block-face scanning electron microscopy, we found no changes in GABAA receptor positivity and size of somatic and dendritic synapses of hippocampal interneurons. We did not find alterations in the level of expression of perineuronal nets around parvalbumin (PV) interneurons or in the density of PV- or somatostatin-positive hippocampal interneurons. However, in contrast to other investigated cell types, PV interneuron axons were occasionally mildly dystrophic around Aβ plaques, and the synapses of PV-positive axon initial segment (AIS)-targeting interneurons were significantly enlarged. Our results suggest that PV interneurons are highly resistant to amyloidosis in APPNL-F mice and amyloid-induced increase in hippocampal pyramidal cell excitability may be compensated by PV-positive AIS-targeting cells. Mechanisms that make PV neurons more resilient could therefore be exploited in the treatment of AD for mitigating Aβ-related inflammatory effects on neurons.

[1]  A. Srikiatkhachorn,et al.  Altered activity in the nucleus raphe magnus underlies cortical hyperexcitability and facilitates trigeminal nociception in a rat model of medication overuse headache , 2019, BMC Neuroscience.

[2]  A. Prochiantz,et al.  Perineuronal nets in brain physiology and disease. , 2019, Seminars in cell & developmental biology.

[3]  F. Edwards A Unifying Hypothesis for Alzheimer’s Disease: From Plaques to Neurodegeneration , 2019, Trends in Neurosciences.

[4]  Yan-Mei Huang,et al.  Major Clinical Trials Failed the Amyloid Hypothesis of Alzheimer's Disease , 2019, Journal of the American Geriatrics Society.

[5]  T. Saido,et al.  Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease , 2019, BMC Neuroscience.

[6]  G. Logroscino,et al.  A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease , 2019, Nature Reviews Neurology.

[7]  L. Dahan,et al.  Early disruption of parvalbumin expression and perineuronal nets in the hippocampus of the Tg2576 mouse model of Alzheimer's disease can be rescued by enriched environment , 2018, Neurobiology of Aging.

[8]  F. Cacucci,et al.  Effects of rising amyloidβ levels on hippocampal synaptic transmission, microglial response and cognition in APPSwe/PSEN1M146V transgenic mice , 2018, bioRxiv.

[9]  Jürgen Götz,et al.  Rodent models for Alzheimer disease , 2018, Nature Reviews Neuroscience.

[10]  T. Freund,et al.  Co-transmission of acetylcholine and GABA regulates hippocampal states , 2018, Nature Communications.

[11]  C. Steinhäuser,et al.  Plaque‐dependent morphological and electrophysiological heterogeneity of microglia in an Alzheimer's disease mouse model , 2018, Glia.

[12]  S. Makin The amyloid hypothesis on trial , 2018, Nature.

[13]  K. Fukunaga,et al.  The Disease-modifying Drug Candidate, SAK3 Improves Cognitive Impairment and Inhibits Amyloid beta Deposition in App Knock-in Mice , 2018, Neuroscience.

[14]  L. Paninski,et al.  Anxiety Cells in a Hippocampal-Hypothalamic Circuit , 2018, Neuron.

[15]  E. Galea,et al.  Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer's disease , 2017, Glia.

[16]  Jason C. Wester,et al.  Hippocampal GABAergic Inhibitory Interneurons. , 2017, Physiological reviews.

[17]  B. Winblad,et al.  APP mouse models for Alzheimer's disease preclinical studies , 2017, The EMBO journal.

[18]  T. Brüning,et al.  Expression of endogenous mouse APP modulates β-amyloid deposition in hAPP-transgenic mice , 2017, Acta neuropathologica communications.

[19]  K. Vossel,et al.  Epileptic activity in Alzheimer's disease: causes and clinical relevance , 2017, The Lancet Neurology.

[20]  J. DeFelipe,et al.  High plasticity of axonal pathology in Alzheimer’s disease mouse models , 2017, Acta neuropathologica communications.

[21]  L. Mucke,et al.  Network abnormalities and interneuron dysfunction in Alzheimer disease , 2016, Nature Reviews Neuroscience.

[22]  S. Itohara,et al.  Cognitive deficits in single App knock-in mouse models , 2016, Neurobiology of Learning and Memory.

[23]  H. Okano,et al.  Modeling neurological diseases with induced pluripotent cells reprogrammed from immortalized lymphoblastoid cell lines , 2016, Molecular Brain.

[24]  C. Brayne,et al.  Microglial immunophenotype in dementia with Alzheimer’s pathology , 2016, Journal of Neuroinflammation.

[25]  Mohan Giri,et al.  Genes associated with Alzheimer’s disease: an overview and current status , 2016, Clinical interventions in aging.

[26]  Takaomi C. Saido,et al.  Familial Alzheimer’s Disease Mutations in Presenilin Generate Amyloidogenic Aβ Peptide Seeds , 2016, Neuron.

[27]  U. Sengupta,et al.  The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy , 2016, EBioMedicine.

[28]  Alzheimer’s Association,et al.  2016 Alzheimer's disease facts and figures , 2016, Alzheimer's & Dementia.

[29]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[30]  D. Nicholson,et al.  Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer’s disease , 2016, Acta Neuropathologica.

[31]  C. Jack,et al.  Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria , 2016, Alzheimer's & Dementia.

[32]  Eric Karran,et al.  The Cellular Phase of Alzheimer’s Disease , 2016, Cell.

[33]  J. Hardy,et al.  Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease , 2016, Current Opinion in Neurobiology.

[34]  H. Shoji,et al.  Age-related changes in behavior in C57BL/6J mice from young adulthood to middle age , 2016, Molecular Brain.

[35]  Angela Yan,et al.  Non-alcoholic fatty liver disease induces signs of Alzheimer’s disease (AD) in wild-type mice and accelerates pathological signs of AD in an AD model , 2016, Journal of Neuroinflammation.

[36]  M. Owen,et al.  Alzheimer's disease: The amyloid hypothesis on trial , 2016, British Journal of Psychiatry.

[37]  E. Verdaguer,et al.  Vulnerability of calbindin, calretinin and parvalbumin in a transgenic/knock-in APPswe/PS1dE9 mouse model of Alzheimer disease together with disruption of hippocampal neurogenesis , 2015, Experimental Gerontology.

[38]  Sagar H. Barage,et al.  Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease , 2015, Neuropeptides.

[39]  F. Edwards,et al.  First effects of rising amyloid-β in transgenic mouse brain: synaptic transmission and gene expression , 2015, Brain : a journal of neurology.

[40]  R. Quirion,et al.  Regional and sub-regional differences in hippocampal GABAergic neuronal vulnerability in the TgCRND8 mouse model of Alzheimer's disease , 2015, Front. Aging Neurosci..

[41]  Jonathan K. Foster,et al.  Bone mineral density, adiposity, and cognitive functions , 2015, Front. Aging Neurosci..

[42]  M. Cordeiro,et al.  Retinal manifestations of Alzheimer's disease. , 2014, Neurodegenerative disease management.

[43]  Peter Jonas,et al.  Fast-spiking, parvalbumin+ GABAergic interneurons: From cellular design to microcircuit function , 2014, Science.

[44]  T. Saido,et al.  New mouse model of Alzheimer's. , 2014, ACS chemical neuroscience.

[45]  Radouil Tzekov,et al.  Vision function abnormalities in Alzheimer disease. , 2014, Survey of ophthalmology.

[46]  S. Itohara,et al.  Single App knock-in mouse models of Alzheimer's disease , 2014, Nature Neuroscience.

[47]  F. Schmitt,et al.  Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models , 2014, Front. Genet..

[48]  E. Siemers,et al.  Amyloid-ß-directed immunotherapy for Alzheimer's disease , 2014, Journal of internal medicine.

[49]  T. Freund,et al.  Quantitative ultrastructural analysis of basket and axo-axonic cell terminals in the mouse hippocampus , 2014, Brain Structure and Function.

[50]  J. Pérez-Ortín,et al.  Cytoplasmic 5′-3′ exonuclease Xrn1p is also a genome-wide transcription factor in yeast , 2013, Front. Genet..

[51]  C. Holmes,et al.  Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization. , 2013, Brain : a journal of neurology.

[52]  George S. B. Williams,et al.  Mitochondrial calcium uptake , 2013, Proceedings of the National Academy of Sciences.

[53]  J. Growdon,et al.  Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. , 2013, Journal of neuropathology and experimental neurology.

[54]  A. Peters,et al.  A website entitled “The fine structure of the aging brain” , 2013, The Journal of comparative neurology.

[55]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[56]  K. Mullane,et al.  Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? , 2013, Biochemical pharmacology.

[57]  J. Nordenström The calcium connection , 2013 .

[58]  A. Wimo,et al.  The global prevalence of dementia: A systematic review and metaanalysis , 2013, Alzheimer's & Dementia.

[59]  G. Paxinos,et al.  Paxinos and Franklin's the Mouse Brain in Stereotaxic Coordinates , 2012 .

[60]  R. Tanzi The genetics of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[61]  Johannes E. Schindelin,et al.  TrakEM2 Software for Neural Circuit Reconstruction , 2012, PloS one.

[62]  R. Miledi,et al.  Loss of functional GABAA receptors in the Alzheimer diseased brain , 2012, Proceedings of the National Academy of Sciences.

[63]  Masahiko Watanabe,et al.  Release probability of hippocampal glutamatergic terminals scales with the size of the active zone , 2012, Nature Neuroscience.

[64]  Daniel Friedman,et al.  Seizures and Epilepsy in Alzheimer's Disease , 2012, CNS neuroscience & therapeutics.

[65]  L. Mucke,et al.  Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.

[66]  J. Fadel,et al.  Interneuron loss reduces dendritic inhibition and GABA release in hippocampus of aged rats , 2012, Neurobiology of Aging.

[67]  P. Jonas,et al.  How the 'slow' Ca2+ buffer parvalbumin affects transmitter release in nanodomain-coupling regimes , 2011, Nature Neuroscience.

[68]  Antonia Gutierrez,et al.  Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer’s mice hippocampus , 2011, Acta Neuropathologica.

[69]  Chengjie Xiong,et al.  Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease , 2011, Alzheimer's Research & Therapy.

[70]  R. Tsien,et al.  Enhancing Serial Block-Face Scanning Electron Microscopy to Enable High Resolution 3-D Nanohistology of Cells and Tissues , 2010 .

[71]  T. Pozzan,et al.  Mitochondria: the calcium connection. , 2010, Biochimica et biophysica acta.

[72]  P. Hof,et al.  Hippocampal interneuron loss in an APP/PS1 double mutant mouse and in Alzheimer’s disease , 2010, Brain Structure and Function.

[73]  M. D'Andrea,et al.  Morphologically distinct types of amyloid plaques point the way to a better understanding of Alzheimer’s disease pathogenesis , 2010, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[74]  Lee L Yu,et al.  Characterization of SiGe Films for Use as a National Institute of Standards and Technology Microanalysis Reference Material (RM 8905) , 2009, Microscopy and Microanalysis.

[75]  Henry Brodaty,et al.  Threat perception in mild cognitive impairment and early dementia. , 2009, The journals of gerontology. Series B, Psychological sciences and social sciences.

[76]  K. Green Calcium in the initiation, progression and as an effector of Alzheimer’s disease pathology , 2009, Journal of cellular and molecular medicine.

[77]  Marie-Claude Potier,et al.  Classification and basic pathology of Alzheimer disease , 2009, Acta Neuropathologica.

[78]  Jeffrey A. James,et al.  Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.

[79]  M. Caballero-Bleda,et al.  Subfield and layer-specific depletion in calbindin-D28K, calretinin and parvalbumin immunoreactivity in the dentate gyrus of amyloid precursor protein/presenilin 1 transgenic mice , 2008, Neuroscience.

[80]  C. Geula,et al.  Cholinergic Neuronal and Axonal Abnormalities Are Present Early in Aging and in Alzheimer Disease , 2008, Journal of neuropathology and experimental neurology.

[81]  M. Beal,et al.  Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. , 2008, Trends in molecular medicine.

[82]  Anatol C. Kreitzer,et al.  Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease , 2007, Neuron.

[83]  Pablo Fuentealba,et al.  Cell Type-Specific Tuning of Hippocampal Interneuron Firing during Gamma Oscillations In Vivo , 2007, The Journal of Neuroscience.

[84]  D. Ulrich,et al.  GABAB receptors: synaptic functions and mechanisms of diversity , 2007, Current Opinion in Neurobiology.

[85]  J. F. López-Téllez,et al.  Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1×APP transgenic model of Alzheimer's disease , 2006, Neurobiology of Aging.

[86]  J. Schneider,et al.  Neuropathology of older persons without cognitive impairment from two community-based studies , 2006, Neurology.

[87]  György Buzsáki,et al.  Populations of hippocampal inhibitory neurons express different levels of cytochrome c , 2006, The European journal of neuroscience.

[88]  Jozsef Csicsvari,et al.  Complementary Roles of Cholecystokinin- and Parvalbumin-Expressing GABAergic Neurons in Hippocampal Network Oscillations , 2005, The Journal of Neuroscience.

[89]  M. Schwartz,et al.  Activation of microglia by aggregated β-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-γ and IL-4 render them protective , 2005, Molecular and Cellular Neuroscience.

[90]  W. Streit Microglia and neuroprotection: implications for Alzheimer's disease , 2005, Brain Research Reviews.

[91]  M. L. de Ceballos,et al.  Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation , 2005, The Journal of Neuroscience.

[92]  P. Riederer,et al.  Perineuronal nets potentially protect against oxidative stress , 2004, Experimental Neurology.

[93]  T. Kosaka,et al.  Immunocytochemical characterization of hippocamposeptal projecting GABAergic nonprincipal neurons in the mouse brain: a retrograde labeling study , 2002, Brain Research.

[94]  G. Buzsáki Theta Oscillations in the Hippocampus , 2002, Neuron.

[95]  J. Hardy,et al.  Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.

[96]  Ralph A. Nixon,et al.  Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.

[97]  Z. Henderson,et al.  Perineuronal nets ensheath fast spiking, parvalbumin‐immunoreactive neurons in the medial septum/diagonal band complex , 2000, The European journal of neuroscience.

[98]  M. Frotscher,et al.  Cerebral Amyloid Induces Aberrant Axonal Sprouting and Ectopic Terminal Formation in Amyloid Precursor Protein Transgenic Mice , 1999, The Journal of Neuroscience.

[99]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[100]  L. Acsády,et al.  Postsynaptic targets of somatostatin-immunoreactive interneurons in the rat hippocampus , 1999, Neuroscience.

[101]  G. Buzsáki,et al.  Interneurons of the hippocampus , 1998, Hippocampus.

[102]  E. Mufson,et al.  Parvalbumin-immunoreactive neurons in the hippocampal formation of Alzheimer's diseased brain , 1997, Neuroscience.

[103]  R. Mrak,et al.  Neuritic plaque evolution in Alzheimer’s disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms , 1997, Acta Neuropathologica.

[104]  John Hardy,et al.  Amyloid, the presenilins and Alzheimer's disease , 1997, Trends in Neurosciences.

[105]  T. Freund,et al.  Differences between Somatic and Dendritic Inhibition in the Hippocampus , 1996, Neuron.

[106]  Carl W. Cotman,et al.  Identification and distribution of axonal dystrophic neurites in Alzheimer's disease , 1993, Brain Research.

[107]  W. Benzing,et al.  Substance P and somatostatin coexist within neuritic plaques: Implications for the pathogenesis of Alzheimer's disease , 1989, Neuroscience.

[108]  R. Katzman.,et al.  Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques , 1988, Annals of neurology.

[109]  F. Bloom,et al.  Somatostatin immunoreactivity in neuritic plaques of Alzheimer's patients , 1985, Nature.

[110]  P. Somogyi,et al.  A new type of specific interneuron in the monkey hippocampus forming synapses exclusively with the axon initial segments of pyramidal cells , 1983, Brain Research.

[111]  M. Wong-Riley,et al.  Histochemical localization of cytochrome oxidase in the hippocampus: Correlation with specific neuronal types and afferent pathways , 1982, Neuroscience.

[112]  M. Abercrombie Estimation of nuclear population from microtome sections , 1946, The Anatomical record.

[113]  J. Zaia,et al.  Extracellular matrix proteomics in schizophrenia and Alzheimer’s disease , 2016, Analytical and Bioanalytical Chemistry.

[114]  K. Hensley Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. , 2010, Journal of Alzheimer's disease : JAD.

[115]  M. Caballero-Bleda,et al.  SUBFIELD AND LAYER-SPECIFIC DEPLETION IN CALBINDIN-D28K, CALRETININ AND PARVALBUMIN IMMUNOREACTIVITY IN THE DENTATE GYRUS OF APP/PS1 TRANSGENIC MICE , 2008 .

[116]  P. Somogyi,et al.  Defined types of cortical interneurone structure space and spike timing in the hippocampus , 2005, The Journal of physiology.

[117]  P. Somogyi,et al.  Spike timing of dendrite-targeting bistratified cells during hippocampal network oscillations in vivo , 2004, Nature Neuroscience.

[118]  P. Somogyi,et al.  Properties of horizontal axo‐axonic cells in stratum oriens of the hippocampal CA1 area of rats in vitro , 2004, Hippocampus.

[119]  B. Hyman,et al.  Microglial response to amyloid plaques in APPsw transgenic mice. , 1998, The American journal of pathology.